# Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

> **NCT02378480** · PHASE3 · COMPLETED · sponsor: **Paratek Pharmaceuticals Inc** · enrollment: 655 (actual)

## Conditions studied

- Bacterial Infections
- Skin Structures and Soft Tissue Infections

## Interventions

- **DRUG:** Omadacycline
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT02378480
- **Lead sponsor:** Paratek Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 655 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02378480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02378480, "Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02378480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*